PHARMARON - Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.’s announcement on the release of the pledge of part of the company’s actual controller’s shares and the postponement of the repurchase of the pledged shares

Pharmaron Beijing Co., Ltd.

Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3759)

Overseas regulatory announcement

This announcement is made by Pharmaron Chemical (Beijing) New Drug Technologies Co., Ltd. (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors

Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.

Chairman

Dr. Lou Pak Leung

People's Republic of China, Beijing

July 31, 2026

As of the date of this announcement, the board of directors includes executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee representative director Mr. Li Chengzong; non-executive director Ms. Wan Xuan; independent non-executive directors Ms. Li Lihua, Professor Zeng Jinfeng and Ms. Shen Rong.

Securities code: 300759 Securities abbreviation: Pharmaron Announcement Number: 2026-054

Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.

Announcement on the release of the pledge of part of the company's actual controller's shares and the postponement of the repurchase of the pledged shares

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

1. Basic information on the release of pledge of shareholders’ shares and the deferred repurchase of pledged shares

Pharmaron Chemicals (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the "Company") recently received a letter from Ms. Zheng Bei, one of the actual controllers of the company, and learned that Ms. Zheng Bei had unpledged part of the company's shares she held and had extended the repurchase of some of the pledged shares. The details are as follows:

1. Basic information on the release of pledge of shares this time

Whether it is a holding

This time the pledged shares of the company are released

shareholder name shareholder or first

Number of pledged shares Total share capital Starting date Release date The pledgee is called the major shareholder and his/her

(share) ratio ratio

persons acting in concert

Actual controller of Cathay Haitong July 2025 July 2026

Zhengbei 350,000 2.22% 0.02% Securities shares on January 30th

Co., Ltd. 2. Basic situation of the delayed repurchase of pledged shares

Whether it is an extension of control

Whether the stock

Whether shareholders or the company they hold shares will repurchase

The amount pledged in the east is the original pledge used to make up for the pledge.

The total share capital of the largest shareholding is limited to the name of the pledgee (share), starting date of pledge, expiration date, and

Dong and its one-proportion shares were pledged to

Deposit

Date of action

2027 Cathay Pacific Exchange Deposit

2025 2026

Zheng actually controls Year 7 Tong Securities Finance

7,000,000 44.44% 0.38% Whether July 30 July 30

Beiren January 30th Shares and organic financing day

The delayed repurchase of part of the pledged shares by the Japanese company's capital is a normal extension carried out by Ms. Zheng Bei based on her capital needs.

During the period, it has the ability to perform the contract, there is no liquidation risk for its pledged shares, and it is not responsible for major asset restructuring.

and other performance compensation obligations will not have a significant impact on the company's production operations and corporate governance, and the actual control

People and those acting in concert will also actively prevent risks.

2. Accumulated pledge of shareholders’ shares

As of the date of announcement, the pledge of shares held by the above-mentioned actual controllers and persons acting in concert is as follows:

The situation of public ownership of pledged shares and unpledged shares. This resolution of pledge. This resolution of pledge.

The total number of shares held by the company has been pledged and has been unoccupied

Number of shares held before pledged Pledged after pledge Unpledged shares Shareholder name proportion Shares restricted and pledged (shares) Number of shares Number of shares restricted and (%) Proportion proportion frozen, target shares shares (shares) (shares) frozen number (%) (%) recorded number proportion proportion (shares)

(shares) (%) (%)

Lou Xiaoqiang 60,540,050 3.30 34,974,000 34,974,000 57.77 1.90 34,974,000 100 10,431,037 40.80

Ningbo Longtai

Kang Investment Management

40,135,026 2.18 12,780,000 12,780,000 31.84 0.70 0 0 0 0Limited Company

Division

Pharmaron

Holdings 180,496,500 9.82 0 0 0 0 0 0 0 0 Limited

Zhengbei 15,750,000 0.86 7,350,000 7,000,000 44.44 0.38 7,000,000 100 4,812,500 55.00

Beihai Duotai

Venture capital 21,956,986 1.20 3,190,000 3,190,000 14.53 0.17 0 0 0 0 Co., Ltd.

Anyi Longtai

Zhongxin Enterprise

Management partnership 4,333,988 0.24 0 0 0 0 0 0 0 0 Enterprises (with

limited partnership)

Total 323,212,550 17.59 58,294,000 57,944,000 17.93 3.15 41,974,000 72.44 15,243,537 5.75

Note: 1. The total number of "proportion of shares held" in the above table is the total number of pledged shares accounted for by the actual controller and its consortium.

The proportion of the total number of company shares held by Dongren.

2. Any discrepancies between the total number and the sum of the sub-items in this announcement are due to rounding.

As of the date of the announcement, the shares held by the company’s actual controller and its persons acting in concert have not been frozen.

According to the situation, there is no risk of liquidation of the pledged shares. The above-mentioned pledge of shares will not lead to a change in the company's actual control rights and will not have a significant impact on the company's production, operation and corporate governance. The actual controller and its concerted actors will also actively prevent risks.

3. Documents available for inspection

4. Proof of release of pledge and deferred repurchase of shares;

5. Detailed list of securities pledge and judicial freezing of China Securities Depository and Clearing Co., Ltd.; 3. Other documents required by Shenzhen Stock Exchange.

Announcement is hereby made.

Board of Directors of Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.

July 31, 2026